A Retrospective Analysis of the First 41 mCRPC Patients with Bone Pain Treated with Radium-223 at the National Institute of Oncology in Hungary
| Autor: | Istvan Bodrogi, Krisztián Nagyiványi, Zs Küronya, Magdolna Dank, Péter Ágoston, István Sinkovics, Krisztina Bíró, Á Rúzsa, Lajos Géczi, Zs Kolonics, Fruzsina Gyergyay, I Böde, T Vajdics |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Radium-223
Male Cancer Research medicine.medical_specialty Anemia Nausea Antineoplastic Agents Bone Neoplasms Single Center 030218 nuclear medicine & medical imaging Pathology and Forensic Medicine 03 medical and health sciences Prostate cancer 0302 clinical medicine Internal medicine Medicine Humans Adverse effect Bone pain Aged Retrospective Studies Aged 80 and over Radioisotopes Hungary business.industry Medical record General Medicine Cancer Pain Middle Aged medicine.disease Surgery Prostatic Neoplasms Castration-Resistant Oncology 030220 oncology & carcinogenesis medicine.symptom Radiopharmaceuticals business medicine.drug Radium |
| Zdroj: | Pathology oncology research : POR. 23(4) |
| ISSN: | 1532-2807 |
| Popis: | Radium-223 dichloride is an alpha-emitting radiopharmaceutical which significantly prolongs overall survival in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases. This was a retrospective analysis of the efficacy and safety of Radium-223 in the first 41 patients treated at a single center in Hungary. Radium-223 was given at a dose of 50 kBq/kg intravenously every 4 weeks for up to 6 cycles. Between 23rd July 2014 and 23rd February 2016, 41 patients were treated. Patient demographics, laboratory values, treatment outcomes and adverse events were collected from medical records. The mean age was 72.2 years (SD: 7.1). 24 patients received Radium-223 as first-line treatment (58%), 7 patients as second (17%), 3 as third (7.3%), 6 as (14.6%), and 1 as fifth-line therapy (2.4%). The mean number of cycles administered was 5.5 (SD: 1.1). The most common side effects were anemia (32% grade 1–3), nausea (28%, grade 1), diarrhea (4%, grade 2), thrombocytopenia (4%, grade 3). The mean baseline PSA level was 307.2 ng/ml (SD: 525.7), which increased to a mean value of 728.5 ng/ml (SD: 1277) by the end of treatment. The baseline mean ALP of 521.1 U/L (SD: 728) decreased to 245.1 U/L (SD: 283.5). The majority of patients experienced a decrease (37%) or complete cessation (43%) of bone pain intensity. In our symptomatic prostate cancer patient population, Radium-223 proved to be efficient in terms of pain relief, with moderate side effects. No PSA response was detected, while alkaline phosphatase levels significantly decreased. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink